On November 14th, the 93rd API China successfully concluded in Chongqing. As a professional manufacturer of silica making its second appearance at API this year, Bangkai fully demonstrated its product strength in silica innovation capabilities and customized service capabilities, conducted multi-level business exchanges, and discussed industry market demands and trends with peers in the industrial chain. It showcased stable professional capabilities and an open cooperative attitude, and built a bridge for efficient collaboration between new and existing partners through its service capabilities covering the entire pharmaceutical industry chain and international product layout.

2025 is regarded as a crucial year for accelerated innovation and momentum restructuring in the pharmaceutical industry, and the 93rd API China has delivered an impressive year-end performance for the sector. The three-day exhibition focused on presenting the latest achievements in pharmaceutical manufacturing, and through intensive exchanges and trend-sharing, it brought more possibilities for industrial collaboration and supply chain optimization.

During the exhibition, more than 30 high-level professional forums were held, focusing on core topics such as pharmaceutical R&D, quality control, and environmental safety. Over 100 industry experts and leaders of leading enterprises were invited to share insights, providing valuable industry experience and cutting-edge perspectives for participants.

As a new materials manufacturer with 17 years of expertise in silica, Bangkai Pharmaceutical is continuously strengthening its core competitiveness in fields such as pharmaceutical separation and purification, pharmaceutical excipients, and R&D and testing chromatographic consumables. It relies on a unique full-chain independently controlled high-purity silica production system and is driven by the technical scenario innovation of "one-base, multiple-products". In recent years, the company has focused on tackling key challenges in emerging business areas including silica microsphere fillers, high-end pharmaceutical excipients, and functional food additives. It has built an industrial ecosystem of "refined customization + multi-field synergy", providing strong support for shaping a more resilient and market-competitive industrial chain.

At the exhibition site, the company's marketing team conducted comprehensive and multi-field cooperation negotiations and exchanges with new and existing customers gathered in the mountain city. They not only showcased the company's innovative product achievements but also detailed Bangkai's R&D and innovation capabilities, product layout, large-scale production advantages, customized service model, and sound quality management system. This further consolidated the foundation for cooperation and opened up broader prospects for collaboration.

With international-aligned production control, continuous R&D investment, innovation accumulation, and full industrial chain service capabilities, Bangkai has become a preferred partner for numerous pharmaceutical enterprises. This exhibition is not only an important window to showcase the corporate brand but also a strategic opportunity to deepen industrial chain cooperation and expand the market. Bangkai will continue to advance its international layout, strengthen technological R&D, and deepen quality management, empowering the high-quality development of the pharmaceutical field with more high-quality products and services.

Bangkai also looks forward to meeting industry peers again on a broader stage to jointly witness the innovation and future of China's pharmaceutical industry.